BRPI0716319A8 - método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano - Google Patents

método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano Download PDF

Info

Publication number
BRPI0716319A8
BRPI0716319A8 BRPI0716319A BRPI0716319A BRPI0716319A8 BR PI0716319 A8 BRPI0716319 A8 BR PI0716319A8 BR PI0716319 A BRPI0716319 A BR PI0716319A BR PI0716319 A BRPI0716319 A BR PI0716319A BR PI0716319 A8 BRPI0716319 A8 BR PI0716319A8
Authority
BR
Brazil
Prior art keywords
human
developing
reducing
hyperphosphatomy
risk
Prior art date
Application number
BRPI0716319A
Other languages
English (en)
Inventor
Helvig Christian
Hellestad Erica
Crawford Keith
Cook Mark
Petrovich Martin
Original Assignee
Aovatechnologies Inc
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aovatechnologies Inc, Wisconsin Alumni Res Found filed Critical Aovatechnologies Inc
Publication of BRPI0716319A2 publication Critical patent/BRPI0716319A2/pt
Publication of BRPI0716319A8 publication Critical patent/BRPI0716319A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método para reduzir a absorção de fosfato em um indivíduo animal humano ou não - humano correndo o risco de desenvlover ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano. trata-se de um método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia. o método inclui a etapa de administração oral ao indivíduo de um anticorpo cotransportador de fosfato de sódio anti-intestinal do tipo 2b (npt 2b) em uma quantidade eficaz para reduzir ou manter a concentração de fosfato de soro no indivíduo.
BRPI0716319A 2006-10-25 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano BRPI0716319A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86287606P 2006-10-25 2006-10-25
US60/862,876 2006-10-25
PCT/US2007/082247 WO2008051980A2 (en) 2006-10-25 2007-10-23 Methods of reducing phosphate absorption

Publications (2)

Publication Number Publication Date
BRPI0716319A2 BRPI0716319A2 (pt) 2013-02-13
BRPI0716319A8 true BRPI0716319A8 (pt) 2019-02-05

Family

ID=39205304

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716319A BRPI0716319A8 (pt) 2006-10-25 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano

Country Status (9)

Country Link
US (1) US8802094B2 (pt)
EP (1) EP2076286B1 (pt)
JP (1) JP5535638B2 (pt)
CN (1) CN101568349B (pt)
AU (1) AU2007309029B2 (pt)
BR (1) BRPI0716319A8 (pt)
CA (1) CA2667524C (pt)
ES (1) ES2573636T3 (pt)
WO (1) WO2008051980A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667613A1 (en) 2006-10-26 2008-06-05 Wisconsin Alumni Research Foundation Methods for reducing phosphate absorption
MX2012006072A (es) * 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
JP7279026B2 (ja) 2017-09-20 2023-05-22 メルサナ セラピューティクス インコーポレイテッド Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法
WO2020037225A1 (en) 2018-08-17 2020-02-20 Mersana Therapeutics, Inc. Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689717T2 (de) 1985-11-25 1994-10-20 Gen Corp Kk Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung.
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
AU1526995A (en) 1994-01-13 1995-08-01 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations, The Antibodies specific for d-myo-inositol 1,4,5-trisphosphate
KR100406912B1 (ko) 1994-08-05 2004-02-18 위스콘신 얼럼나이 리서어치 화운데이션 사료효율을향상시키기위하여사용되는cck항체
US5597815A (en) * 1995-07-13 1997-01-28 Wisconsin Alumni Research Foundation Prevention of hyperphosphatemia in kidney disorder patients
TW528597B (en) 1996-03-05 2003-04-21 Mitsubishi Electric Corp Medicament for preventive and/or therapeutic treatment of hyperphosphatemia
EP0922461A4 (en) 1996-07-19 2002-07-17 Nikken Chemicals Co Ltd MEDICINE AGAINST HYPERPHOSPHATANEMIA
EP0930891A4 (en) 1996-10-02 2001-07-04 Ovimmune Inc ORAL ADMINISTRATION OF CHICKEN EGG ANTIBODIES FOR TREATING DISEASES
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CH694588A5 (de) 1999-02-09 2005-04-15 Hoffmann La Roche Menschliche intestinale Npt2B.
US6213930B1 (en) 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
CA2395840A1 (en) 1999-12-27 2001-07-05 The University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
WO2002003788A2 (en) 2000-07-06 2002-01-17 Deltagen, Inc. Transgenic mice containing targeted phosphatase gene disruptions
WO2005099753A1 (en) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
CA2667613A1 (en) 2006-10-26 2008-06-05 Wisconsin Alumni Research Foundation Methods for reducing phosphate absorption

Also Published As

Publication number Publication date
BRPI0716319A2 (pt) 2013-02-13
US8802094B2 (en) 2014-08-12
US20100166760A1 (en) 2010-07-01
ES2573636T3 (es) 2016-06-09
CA2667524A1 (en) 2008-05-02
EP2076286A2 (en) 2009-07-08
WO2008051980A3 (en) 2008-06-19
EP2076286B1 (en) 2016-03-09
WO2008051980A2 (en) 2008-05-02
CA2667524C (en) 2017-02-07
JP5535638B2 (ja) 2014-07-02
CN101568349B (zh) 2012-09-19
WO2008051980A8 (en) 2009-05-28
JP2010508283A (ja) 2010-03-18
AU2007309029B2 (en) 2013-05-09
CN101568349A (zh) 2009-10-28
AU2007309029A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
CA3118834C (en) Resetting biological pathways for defending against and repairing deterioration from human aging
Kaye et al. Folic acid supplementation in patients with elevated homocysteine levels
Bingül et al. Betaine treatment decreased oxidative stress, inflammation, and stellate cell activation in rats with alcoholic liver fibrosis
Yu et al. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling
BRPI0716319A8 (pt) método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano
Bingül et al. High-fat diet plus carbon tetrachloride-induced liver fibrosis is alleviated by betaine treatment in rats
Bertolo et al. The nutritional burden of methylation reactions
Onaolapo et al. Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono-or adjunct therapy
BRPI0519391B1 (pt) composição e uso da mesma para promover a saúde oral em um animal de companhia e kit para administração da composição
Yun et al. Plasma homocysteine level and hepatic sulfur amino acid metabolism in mice fed a high-fat diet
Trumble The use of nutraceuticals for osteoarthritis in horses
Shirvani et al. The effects of high-intensity interval training vs. moderate-intensity continuous training on serum irisin and expression of skeletal muscle PGC-1α gene in male rats
Ma et al. Methotrexate improves perivascular adipose tissue/endothelial dysfunction via activation of AMPK/eNOS pathway
Rosenfeld et al. Nutrition and dietary supplements in motor neuron disease
Wang et al. Treatment with Shuyu capsule increases 5-HT1AR level and activation of cAMP-PKA-CREB pathway in hippocampal neurons treated with serum from a rat model of depression
Huang et al. Pre-gestational stress alters stress-response of pubertal offspring rat in sexually dimorphic and hemispherically asymmetric manner
BRPI0416731A (pt) métodos para a redução de quantidade de desulfovibrio e/ou helicobacter spp. no trato gi de um animal de estimação, para tratamento de uma inflamação do trato gi em um animal de estimação, e para a redução de um odor
Aldbass et al. Protective and therapeutic potency of N-acetyl-cysteine on propionic acid-induced biochemical autistic features in rats
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
Mirza et al. In vitro assessment of the combined effect of eicosapentaenoic acid, green tea extract and curcumin C3 on protein loss in C 2 C 12 myotubes
Carter et al. Isoaspartate, carbamoyl phosphate synthase-1, and carbonic anhydrase-III as biomarkers of liver injury
BRPI0716317A8 (pt) método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano
BRPI0807601B8 (pt) método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
Zhang et al. The effect of increasing concentrations of DL-methionine and 2-hydroxy-4-(methylthio) butanoic acid on hepatic genes controlling methionine regeneration and gluconeogenesis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]